You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科兴称新冠疫苗对3至17岁儿童似乎安全 可引发免疫反应
阿思达克 03-23 15:51
《路透》报道,科兴生物(SVA.US)表示,根据早期和中期临床试验的初步结果,公司研发的新型冠状病毒疫苗,对3至17岁儿童似乎是安全,能够在儿童和青少年身上引发免疫反应。不过有关初步数据尚未在同行评审的医学杂志上发表。

科兴医学总监曾刚在北京的学术会议上表示,初步数据涉及550多名3至17岁的测试者,他们接种了两次低、中剂量的疫苗或安慰剂。曾刚称测试中有两名儿童在注射较低剂量後发高烧,其余大多数的不良反应都属轻微。

曾刚又指,临床试验显示科兴疫苗在儿童和青少年身上产生的抗体水平,高过18至59岁的成年人,及早期临床试验中的老年人。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account